Senisca

Executive Summary

Senisca is a UK-based biotechnology company pioneering RNA-based senotherapeutics that address dysregulated RNA splicing as a novel hallmark of cellular aging. Founded in 2018 and spun out from the University of Exeter, the company aims to reverse senescence by restoring youthful levels of splicing factors, thereby treating age-related diseases such as fibrosis, osteoarthritis, and neurodegenerative disorders. With a unique approach that targets the fundamental biology of aging, Senisca is positioned at the forefront of the senolytic/senomorphic field. The company is currently in the pre-clinical stage, focusing on lead optimization and proof-of-concept studies. While no funding rounds have been disclosed, Senisca likely requires significant capital to advance its platform towards clinical trials. Key upcoming milestones include securing Series A funding, demonstrating in vivo efficacy in disease models, and initiating IND-enabling toxicology studies. The technology has potential broad applicability, but risks include translational challenges and competition from other senotherapeutics. Assuming successful advancement, Senisca could become a leader in the aging biology space.

Upcoming Catalysts (preview)

• Q1 2026Series A financing round70% success
• Q2 2026Preclinical in vivo efficacy data readout60% success
• Q4 2026IND-enabling studies initiation or partnership50% success